EU Approves TEVIMBRA for Perioperative Lung Cancer

Published on: LinkedIn (Spencer Knight)

The European Commission has approved TEVIMBRA (tislelizumab) from BeOne Medicines, the first PD-1 inhibitor to demonstrate overall survival benefit in perioperative non-small cell lung cancer. Based on the RATIONALE-315 trial, TEVIMBRA showed significant improvements in overall and event-free survival when used with chemotherapy and as monotherapy, expanding its approvals to nine tumor indications across Europe.

👉 Read the full article: BeOne’s TEVIMBRA Approved in the EU

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.